Tissue Regenix group inks deal, expands DermaPure access in US

Shayna Korol -   Print  |

U.K.-based Tissue Regenix Group inked a deal with Premier for TRX's flagship product DermaPure to maintain access to 3,900 hospitals and more than 150,000 healthcare providers in the U.S., according to proactiveinvestors UK.

The three-year implantable products contract between subsidiary TRX BioSurgery and healthcare improvement company Premier kicks off July 1, building off of the companies' 'Breakthrough Technology Agreement' signed in December 2016.

DermaPure is a decellurized human dermis used in acute and chronic wound care, orthopedic trauma and dental applications. After TRX formed an exclusive distribution agreement with ARMS medical, DermaPure may also be used in urogynecology and urology.

More articles on biologics:

Infuse gets new FDA indication for lateral, anterior spinal fusions with PEEK implants: 5 things to know

Dr. Domagoj Coric treats 1st patient in DiscGenics' trial to treat degenerative disc disease: 5 insights

4 things to know about Datum Orthobiologics, a newly formed company

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers